The DOI matches its Crossref record; 190 of the 190 references it cites were found in a registry or an index.
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
Open accessAbstract
The epidemiology of invasive fungal infections is changing, with new populations at risk and the emergence of resistance caused by the selective pressure from increased usage of antifungal agents in prophylaxis, empiric therapy, and agriculture. Limited antifungal therapeutic options are further challenged by drug-drug interactions, toxicity, and constraints in administration routes. Despite the need for more antifungal drug options, no new classes of antifungal drugs have become available over the last 2 decades, and only one single new agent from a known antifungal class has been approved in the last decade. Nevertheless, there is hope on the horizon, with a number of new antifungal classes in late-stage clinical development. In this review, we describe the mechanisms of drug resistance employed by fungi and extensively discuss the most promising drugs in development, including fosmanogepix (a novel Gwt1 enzyme inhibitor), ibrexafungerp (a first-in-class triterpenoid), olorofim (a novel dihyroorotate dehydrogenase enzyme inhibitor), opelconazole (a novel triazole optimized for inhalation), and rezafungin (an echinocandin designed to be dosed once weekly). We focus on the mechanism of action and pharmacokinetics, as well as the spectrum of activity and stages of clinical development. We also highlight the potential future role of these drugs and unmet needs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fosmanogepix inhibits the inositol acyltransferase Gwt1 which catalyzes and early step in the glycosylphosphatidylinositol (GPI) anchor biosynthesis pathway, thereby preventing GPI-anchored protein maturation, a process critical for linkages between different components of the fungal cell wall [39,46].”
From Antifungal therapy of Candida biofilms: Past, present and future (2023) · cites this paper as [39]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Ibrexafungerp is another novel agent which inhibits (1→3)-β-D-glucan synthesis at a different site than echinocandins and thus retains activity against many organisms with echinocandin resistance due to FKS mutations, including many strains of C. auris.156”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [156]
The cited source says what the claim attributes to it.
In the citing paper
“It has oral bioavailability of 35–50% and good systemic distribution except for the CNS.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [156]
The cited source says what the claim attributes to it.
In the citing paper
“Ibrexafungerp is currently only FDA approved as oral therapy for vulvovaginal candidiasis, although clinical trials for invasive candidiasis step-down therapy, refractory candidiasis, and C. auris are ongoing.149,156–159”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [156]
In the citing paper
“At the present time there are a handful of investigational agents at different stages of the antifungal development pipeline. Although the majority still target ergosterol (same as azoles) or 1,3-β-D-glucan (same as echinocandins), they also include some novel classes with novel targets and mechanisms [25,39,40].”
From Antifungal therapy of Candida biofilms: Past, present and future (2023) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
J Antimicrob Chemother 1994; 33: 350–351
O'SHAUGHNESSY, E. M., & DAS, S. S. (1994) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/33.2.350 · Cited by 3,746
Cornely, O. A., Alastruey-Izquierdo, A., Arenz, D., Chen, S. C. A., Dannaoui, E., Hochhegger, B., Hoenigl, M., Jensen, H. E., Lagrou, K., Lewis, R. E., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30312-3 · Cited by 1,820
Self-citationDenning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131 · cited 1×
“an N-linked acyl lipid side-chain [187] that is considered essential for the antifungal activity [188].”
BackgroundThe global problem of antifungal resistance: prevalence, mechanisms, and management
Perlin, D. S., Rautemaa-Richardson, R., & Alastruey-Izquierdo, A. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30316-x · Cited by 1,055
Maertens, J. A., Raad, I. I., Marr, K. A., Patterson, T. F., Kontoyiannis, D. P., Cornely, O. A., Bow, E. J., Rahav, G., Neofytos, D., Aoun, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01159-9 · Cited by 1,001
Self-citationKoehler, P., Bassetti, M., Chakrabarti, A., Chen, S. C. A., Colombo, A. L., Hoenigl, M., Klimko, N., Lass-Flörl, C., Oladele, R. O., Vinh, D. C., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30847-1 · Cited by 951 · cited 1×
“In addition, new manifestations of disease in the intensive care population such as coronavirus disease 2019 (COVID-19)-associated aspergillosis [10–13] and mucormycosis [14, 15] are posing major problems because of extensive drug–drug interactions of antifungal drugs [16].”
BackgroundSelf-citationAneuploidy and Isochromosome Formation in Drug-Resistant Candida albicans
Selmecki, A., Forche, A., & Berman, J. (2006) · Science · doi:10.1126/science.1128242 · Cited by 733
Drug resistance and tolerance in fungi.
Berman, J., & Krysan, D. J. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0322-2 · Cited by 642 · cited 21×
“Candida dubliensis, C. fabianii, C. glabrata, C. inconspicua, C. kefyr, C. krusei, C. lipolytica, C. pulcherrima, C. sojae, and C. tropicalis were also inhibited by MIC values ≤ 0.125 µg/mL and were susceptible to other echinocandins using epidemiological cut-off value (ECV) interpretive criteria [194, 195].”
BackgroundInfluentialChowdhary, A., Prakash, A., Sharma, C., Kordalewska, M., Kumar, A., Sarma, S., Tarai, B., Singh, A., Upadhyaya, G., Upadhyay, S., et al. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx480 · Cited by 577 · cited 1×
“At the same time, the emergence of Candida auris [7], as well as azole-resistant Aspergillus fumigatus [8], and cryptic species that are morphologically indistinguishable by classical methods within main Aspergillus sections [9] pose additional threats to our current antifungal armamentarium.”
BackgroundThe ALS gene family of Candida albicans.
Hoyer, L. L. (2001) · Trends in Microbiology · doi:10.1016/s0966-842x(01)01984-9 · Cited by 540
Research works printed but not linked: 9
- Vale-Silva L, Ischer F, Leibundgut-Landmann S, Sanglard D. Gain-of-function mutations in PDR1, a regulator of antifungal drug resistance in Candida glabrata, control adherence to host cells. Infect Immun. 2013;81(5):1709–20. · DOI · Paper page
- Hagiwara D, Miura D, Shimizu K, Paul S, Ohba A, Gonoi T, et al. A novel Zn2-Cys6 transcription factor AtrR plays a key role in an azole resistance mechanism of Aspergillus fumigatus by co-regulating cyp51A and cdr1B expressions. PLoS Pathog. 2017;13(1):e1006096. · DOI · Paper page
- Ghannoum M, Long L, Larkin EL, Isham N, Sherif R, Borroto-Esoda K, et al. SCY-078, a novel oral glucan synthase inhibitor, for the treatment of invasive aspergillosis: evaluation of antifungal activity singly and in combination. Antimicrob Agents Chemother. 2018;62(6):e00244-18. · DOI · Paper page
- Trucksis M, Garrett G, Heriman I. A phase I multiple rising dose study evaluating safety, tolerability, and pharmacokinetics of MK-3118, oral glucan synthase inhibitor, in healthy volunteers. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2011; Chicago (IL).
- Kennedy T AG, Steiner J, Heep M, Oliver J, Sibley G, Law D., editor Multiple dose pharmacokinetics of an immediate-release tablet formulation of F901318 in healthy male and female subjects. In: Proceedings of the 27th European congress of clinical microbiology and infectious diseases; 22–25 April 2017; Vienna.
- Kennedy TAG, Steiner J, Heep M, Oliver J, Sibley G, Law D, editor Assessment of the duraiton of infusion on the tolerability and repaet dose pharmacokinetics of F901318 in health-volunteers (abstract P1711). In: Proceedings of the 27th European congress of clinical microbiology and infectious diseases; 22-25 April 2017; Vienna.
- Tio SH TK, Ng G, Rex JH, Carney D, Slavin M. Olorofim for a case of severe disseminated Lomentospora prolificans infection. In: Proceedings of the 30th European Congress of Clinical Microbiology and Infectious Diseases; 18–21 April 2020; Paris.
- Chen S RN, Cunneen S, Cornelissen K, Rex JH, Heath CH, Harvey E. A case of Lomentospora prolificans treated with the novel antifungal olorofim. In: Proceedings of the 30th European Congress of Clinical Microbiology and Infectious Diseases; 18–21 April 2020; Paris.
- Harvey EFL, Rex JH, Thompson G. Successful use of the novel antifungal olorofim in the treatment of dissemianted coccidioidomycosis. Proceedings of the 30th European Congress of Clinical Microbiology and Infectious Diseases; 18-21 April 2020; Paris.
Cited by
Pathogenesis and virulence of Candida albicans
Lopes, J. P., & Lionakis, M. S. (2022) · Virulence · doi:10.1080/21505594.2021.2019950 · Cited by 477
“review of the new antifungal agents in clinical development the reader is refered to [409].”
BackgroundCOVID-19-associated fungal infections
Hoenigl, M., Seidel, D., Sprute, R., Cunha, C., Oliverio, M., Goldman, G. H., Ibrahim, A. S., & Carvalho, A. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01172-2 · Cited by 482
Self-citationThe importance of antimicrobial resistance in medical mycology
Gow, N. A. R., Johnson, C., Berman, J., Coste, A. T., Cuomo, C. A., Perlin, D. S., Bicanic, T., Harrison, T. S., Wiederhold, N., Bromley, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32249-5 · Cited by 224
Self-citationThe WHO fungal priority pathogens list: a crucial reappraisal to review the prioritisation
Casalini, G., Giacomelli, A., & Antinori, S. (2024) · The Lancet Microbe · doi:10.1016/s2666-5247(24)00042-9 · Cited by 197
Structural and mechanistic insights into fungal β-1,3-glucan synthase FKS1
Hu, X., Yang, P., Chai, C., Liu, J., Sun, H., Wu, Y., Zhang, M., Zhang, M., Liu, X., & Yu, H. (2023) · Nature · doi:10.1038/s41586-023-05856-5 · Cited by 213
Metadata
- Authors
- Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., Wiederhold, N., & Jenks, J. D.
- Affiliations
- Medical University of Graz (AT)
- University of Cologne (DE)
- Hackensack Meridian Health (US)
- Washington University in St. Louis (US)
- University of California Davis Medical Center (US)
- The University of Texas at San Antonio Health Science Center (US)
- University of California San Diego (US)
- Corresponding author
- Hoenigl, Martin
- ORCID
- Venue
- Drugs
- Published
- 2021-10
- Volume
- 81
- Issue
- 15
- Pages
- 1703-1729
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- PMC
- PMC8501344
- OpenAlex
- W3202074216
- Cited by
- 467
- References
- 188
- Citations by year
- 2026: 78 · 2025: 116 · 2024: 117 · 2023: 98 · 2022: 54 · 2021: 3
- FWCI
- 7.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor, 8 d)
- Locations
- Drugs (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by-nc)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- national institute of allergy and infectious diseases (UL1TR001442)
- Medical University of Graz
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- antifungal drug development, fosmanogepix, ibrexafungerp, olorofim, rezafungin, invasive fungal infections, antifungal resistance mechanisms, triterpenoids, triazoles, echinocandins, pharmacokinetics, drug-drug interactions, unmet medical needs
- MeSH terms
- Invasive Fungal Infections, Drug Development, Animals, Antifungal Agents, Drug Interactions, Fungi, Humans, Drug Resistance, Fungal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. https://app.cochat.ai/papers/10.1007/s40265-021-01611-0
- The paper
- Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., Wiederhold, N., & Jenks, J. D. (2021). The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. Drugs. https://doi.org/10.1007/s40265-021-01611-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.